<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02761252</url>
  </required_header>
  <id_info>
    <org_study_id>MEIN/15/Bil-ARC/001</org_study_id>
    <secondary_id>2015-004806-40</secondary_id>
    <nct_id>NCT02761252</nct_id>
  </id_info>
  <brief_title>Efficacy of Co-administration of Bilastine and Montelukast in Patients With SARC and Asthma</brief_title>
  <acronym>SKY</acronym>
  <official_title>Bilastine and Montelukast in Patients With Seasonal Allergic Rhinoconjunctivitis and Asthma: Efficacy of Concomitant Administration - the SKY Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Menarini International Operations Luxembourg SA</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Menarini International Operations Luxembourg SA</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare concomitant administration of Montelukast and
      Bilastine to Montelukast and Bilastine monotherapies in patients with SARC and asthma
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The present study (SKY) was designed to show if once daily oral combination therapy with
      Montelukast 10 mg and Bilastine 20 mg is superior to monotherapy with Bilastine 20 mg in
      patients with Seasonal Allergic RhinoConjunctivitis (SARC) and comorbid mild to moderate
      asthma on total symptom scores (TSS) and if the combination therapy reflects an improvement
      in quality of life as assessed via the Asthma Quality of Life Questionnaire (AQLQ) over a
      longer time period when compared to monotherapies with Montelukast 10 mg and Bilastine 20 mg.
      Mild to moderate asthma was defined according to the criteria of the Global Initiative for
      Asthma, i.e., GINA criteria 2 and 3 (GINA, 2012). The study population included patients
      inadequately controlled on inhaled corticosteroids and in whom &quot;as-needed&quot; short acting
      beta-agonists provided inadequate clinical control.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 13, 2016</start_date>
  <completion_date type="Actual">November 24, 2016</completion_date>
  <primary_completion_date type="Actual">November 24, 2016</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>The study was a randomised (1:1:1), double-blind, double-dummy, interventional, active-controlled, parallel groups (three groups), multi-centre, multi-national, superiority clinical trial. The study plan included a 7-day (± 4) run-in period to ensure wash-out from previous forbidden treatments and to perform the tests required to ensure appropriate patient enrolment into the study. The active treatment period was 12 weeks (85 days) with a follow-up visit (phone call) at 28 days (± 4) after the End of Treatment.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>The principal investigator and study staff, subjects and monitors remained blinded to the treatment until study closure in this double-blind, double-dummy study. The identity of the study drug was revealed only if the subject experienced a medical emergency the management of which would be improved by the knowledge of the blinded treatment assignment.
As the combination therapy of Bilastine + Montelukast consisted of two tablets in contrast to monotherapy with either Bilastine or Montelukast, the double-dummy technique was applied with matching placebo for each Investigation Medicinal Product (IMP) (monotherapy with Bilastine or Montelukast) to ensure the maintenance of double-blind conditions. Therefore, each patient took 2 tablets with each dose administered.
As by randomisation list, each Patient Kit consisted of two IMP treatments (either active + placebo or active + active) in separate blisters packed in two different boxes.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Change From Baseline With Montelukast+Bilastine Compared With Bilastine Monotherapy in SARC Symptoms</measure>
    <time_frame>4 weeks of treatment (from baseline to 4 weeks of treatment)</time_frame>
    <description>To demonstrate that concomitant administration of montelukast and bilastine is superior to bilastine monotherapy in SARC symptoms, as assessed by Total Symptoms Scores (TSS) after 4 weeks of treatment.
Total Symptoms Scores (TSS) assesses nasal (nasal congestion, rhinorrhea, nasal itching, sneezing) and non nasal symptoms (ocular redness, ocular itching, tearing) of rhinoconjuctivits.
Each of the 7 symptoms is scored from 0 (absent) to 3 (severe) as follows:
0 (absent) Symptom not present
1 (mild) Symptom is clearly present but easily tolerated, a nuisance, minimal awareness
2 (moderate) Symptom is bothersome but tolerable, does not interfere with daily activities or sleep
3 (severe) Symptom is hard to tolerate and interferes with daily activities or sleep.
TSS assessment comprises of scoring (0-3) of all 7 above mentioned symptoms. Final TSS scores is in a range from 0-21.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline With Montelukast+Bilastine Compared With Montelukast and Bilastine Monotherapies in Asthma Control</measure>
    <time_frame>After 4 weeks of treatments</time_frame>
    <description>To evaluate the efficacy of concomitant montelukast and bilastine compared with montelukast and bilastine monotherapies in asthma control, as assessed by Asthma Quality of Life Questionnaire (AQLQ) after 4 weeks.
The AQLQ was developed to measure the functional problems (physical, emotional, social and occupational) that are most troublesome to adults (17-70 years) with asthma.
Each of the 32 questionnaire's items will be scored on a 7-point scale (where 7 means &quot;not impaired at all&quot; and 1 means &quot;severely impaired&quot;). The overall AQLQ score is the mean of all 32 responses (https://www.qoltech.co.uk/aqlq.html).
The change in AQLQ score from baseline to 4 weeks after treatment - AQLQ score at baseline for patients with both available values has been the secondary endpoint.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline With Montelukast+Bilastine Compared With Montelukast and Bilastine Monotherapies in SARC Symptoms (DNSS)</measure>
    <time_frame>After 4 weeks of treatment (from baseline)</time_frame>
    <description>To evaluate the efficacy of concomitant montelukast and bilastine compared with montelukast and bilastine monotherapies in daytime symptoms of SARC, as assessed by Daytime Nasal Symptom Score (DNSS) after 4 weeks of treatment.
Daytime Nasal Symptom Score (DNSS) is the average of individual scores of nasal congestion, rhinorrhea, nasal itching, sneezing of rhinoconjuctivits.
Each of the 4 symptoms is scored from 0 (absent) to 3 (severe) as follows:
0 (absent) Symptom not present
1 (mild) Symptom is clearly present but easily tolerated, a nuisance, minimal awareness
2 (moderate) Symptom is bothersome but tolerable, does not interfere with daily activities or sleep
3 (severe) Symptom is hard to tolerate and interferes with daily activities or sleep.
DNSS assessment comprises of scoring (0-3) of all 4 above mentioned symptoms. Final DNSS scores is in a range from 0-12.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline With Montelukast + Bilastine Compared With Montelukast and Bilastine Monotherapies in SARC Symptoms (DNNSS)</measure>
    <time_frame>After 4 weeks of treatment (from baseline)</time_frame>
    <description>To evaluate the efficacy of concomitant montelukast and bilastine compared with montelukast and bilastine monotherapies in daytime symptoms of SARC, as assessed by Daytime Non Nasal Symptom Score (DNNSS) after 4 weeks of treatment.
Daytime Non Nasal Symptom Score (DNSS) is the average of individual scores of ocular redness, ocular itching and tearing of rhinoconjuctivits.
Each of the 3 symptoms is scored from 0 (absent) to 3 (severe) as follows:
0 (absent) Symptom not present
1 (mild) Symptom is clearly present but easily tolerated, a nuisance, minimal awareness
2 (moderate) Symptom is bothersome but tolerable, does not interfere with daily activities or sleep
3 (severe) Symptom is hard to tolerate and interferes with daily activities or sleep.
DNNSS assessment comprises of scoring (0-3) of all 3 above mentioned symptoms. Final DNNSS scores is in a range from 0-9.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Usage of Relief Medication for SARC</measure>
    <time_frame>From baseline to 4 weeks of treatment</time_frame>
    <description>Number of days without any relief medication for SARC</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Usage of Relief Medication for Asthma</measure>
    <time_frame>From baseline to 4 weeks of treatment</time_frame>
    <description>Number of days without any relief medication for Asthma.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">454</enrollment>
  <condition>Seasonal Allergic Rhinoconjunctivitis</condition>
  <condition>Asthma</condition>
  <arm_group>
    <arm_group_label>Bilastine+montelukast</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Bilastine 20 mg, 10 blister containing 10 tablets + Montelukast 10 mg, 10 blister containing 10 film coated tablets each for treatment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Bilastine+placebo montelukast</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Bilastine 20 mg, 10 blister containing 10 tablets + Placebo Montelukast, 10 blister containing 10 film coated tablets each.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Montelukast+placebo bilastine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Placebo Bilastine, 10 blister containing 10 tablets + Montelukast 10 mg, 10 blister containing 10 film coated tablets each.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bilastine 20mg</intervention_name>
    <arm_group_label>Bilastine+montelukast</arm_group_label>
    <arm_group_label>Bilastine+placebo montelukast</arm_group_label>
    <other_name>Robilas</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Montelukast 10mg</intervention_name>
    <arm_group_label>Bilastine+montelukast</arm_group_label>
    <arm_group_label>Montelukast+placebo bilastine</arm_group_label>
    <other_name>Montelukast</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo Bilastine 20mg</intervention_name>
    <arm_group_label>Montelukast+placebo bilastine</arm_group_label>
    <other_name>Placebo Bilastine</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo Montelukast 10mg</intervention_name>
    <arm_group_label>Bilastine+placebo montelukast</arm_group_label>
    <other_name>Placebo Montelukast</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        INCLUSION CRITERIA

          1. Patients aged 18 years or older;

          2. Patients with at least 2 years history of SARC prior to the study and mild to moderate
             asthma (GINA criteria 2 and 3) inadequately controlled on inhaled corticosteroids and
             in whom &quot;as-needed&quot; short acting beta-agonists provide inadequate clinical control;

          3. Forced expiratory volume at one second (FEV1) &gt; 70% of the predicted normal value
             demonstrable at least 6 hours after last short acting β-2 agonist use or 12 hours
             after last long acting β-2 agonist (LABA) use;

          4. Nasal Symptoms Score (NSS) at baseline ≥ 3. Baseline NSS will be defined as the mean
             of the 6 last assessments of the patients' diary (3 last days before randomization);

          5. Positive results of skin prick test on at least one seasonal allergen within the last
             3 years;

          6. Patients who provided a signed written informed consent form;

          7. Patients who are able and willing to complete web-based Patient's Diary;

          8. Patients who agree to maintain consistency in their surroundings throughout the study
             period;

          9. Women of childbearing potential (WOCBP) including peri-menopausal women who have had a
             menstrual period within 1 year have to have a negative pregnancy test. Results have to
             be available until the Visit 2 and negative for the patient to be entered in the
             study.

         10. WOCBP have to use an effective method of birth control throughout the study period and
             for 4 weeks after study completion (defined as a method which results in a failure
             rate of less than 1% per year) such as:

               -  combined (estrogen and progestogen containing) hormonal contraception associated
                  with inhibition of ovulation (oral, intravaginal, transdermal)

               -  progestogen-only hormonal contraception associated with inhibition of ovulation
                  (oral, injectable, implantable)

               -  intrauterine device (IUD)

               -  intrauterine hormone-releasing system (IUS)

               -  bilateral tubal occlusion

               -  vasectomised partner (provided that partner is the sole sexual partner of the
                  trial participant and that the vasectomised partner has received medical
                  assessment of the surgical success)

               -  sexual abstinence In each case of delayed menstrual period (over one month
                  between menstruations) confirmation of absence of pregnancy is strongly
                  recommended. This recommendation also applies to WOCBP with infrequent or
                  irregular menstrual cycles.

        EXCLUSION CRITERIA

          1. Patients with hypersensitivity to any component of the study medications;

          2. Patients with non-allergic rhinoconjunctivitis (e.g. vasomotor, infectious,
             drug-induced);

          3. Presence of nasal polyps or any clinically important nasal anomaly;

          4. History of acute and/or chronic sinusitis within 30 days of Visit 2;

          5. History of eye surgery within 3 months of Visit 2;

          6. History of intranasal surgery within 3 months of Visit 2;

          7. Immunotherapy within 6 months prior to Visit 1;

          8. Upper respiratory infections including cold and systemic infections within 3 weeks of
             Visit 2;

          9. Patients with moderate to severe renal impairment and taking P-gp inhibitors (e.g.
             ketoconazole, erythromycin, cyclosporine, ritonavir, diltiazem) within 7 days prior to
             the first dose of study medication;

         10. Patients requiring daily &quot;controller&quot; medications with cromolyn-type drugs or
             leukotriene antagonists;

         11. Patient required daily &quot;controller&quot; medication with Inhaled corticosteroids (ICS) or
             LABA at medium /high dosage defined by GINA criteria;

         12. Patients with clinically important (based on principal investigator's judgment)
             hepatic impairment;

         13. Patients with severe concomitant disease (based on principal investigator's judgment)
             that could interfere with treatment response;

         14. Patients with QT syndrome;

         15. Patients with Galactose intolerance, Lapp lactase deficiency or glucose- galactose
             malabsorption;

         16. Pregnant or breast-feeding women;

         17. Patients with a mental condition rendering the subject unable to understand the
             nature, scope and possible consequences of the study (based on principal
             investigator's judgment);

         18. Patients who had a recent history (within previous 12 months) of drug addiction or
             alcohol abuse based on Principal investigator's judgment ;

         19. Patients participating in or having participated in another clinical trial within the
             previous three months;

         20. Patients unable to take relief medications due to contraindications or intolerance;

         21. Patients who are taking or have taken any of the following medications prior to
             randomisation in the study and have not complied with the specified washout period:

               -  Antihistaminic drugs or montelukast (7 days)

               -  Systemic or intranasal corticosteroids (4 weeks)

               -  Delayed-release corticosteroids (3 months)

               -  Ketotifen (2 weeks)

               -  Macrolides antibiotics and imidazolic antifungals (systemic)(7 days)

               -  Anticholinergics (7 days)

               -  Drugs with antihistamine properties (phenothiazine) (7 days)

               -  Intranasal and systemic decongestants (3 days)

               -  Lodoxamide (7 days)

         22. Patients who will be operating heavy machinery or need to drive motor vehicles as an
             essential part of their profession.

         23. Patients who are planning to travel outside the study area during the course of the
             study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Massimo Pistolesi, Prof</last_name>
    <role>Study Director</role>
    <affiliation>AOUC Azienda Ospedaliero-Universitaria Careggi</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Oliviero Rossi, Prof</last_name>
    <role>Study Director</role>
    <affiliation>AOUC Azienda Ospedaliero-Universitaria Careggi</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Cakovec</city>
        <country>Croatia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Rijeka</city>
        <country>Croatia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Zagreb</city>
        <country>Croatia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Brno</city>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Ostrava Hrabuvka</city>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Teplice</city>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Dreieich</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Heidelberg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Catania</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Florence</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Modena</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Pavia</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Verona</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Riga</city>
        <country>Latvia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bialystok</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bielsko-Biala</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Gdansk</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Katowice</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Krakow</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Lodz</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Lublin</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Nowy Duninow</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Poznan</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Rzeszow</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tarnow</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Wroclaw</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Brasov</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bucharest</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Cluj Napoca</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Ploieşti</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bardejov</city>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Levice</city>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Croatia</country>
    <country>Czechia</country>
    <country>Germany</country>
    <country>Italy</country>
    <country>Latvia</country>
    <country>Poland</country>
    <country>Romania</country>
    <country>Slovakia</country>
  </location_countries>
  <removed_countries>
    <country>Czech Republic</country>
  </removed_countries>
  <verification_date>April 2019</verification_date>
  <study_first_submitted>April 28, 2016</study_first_submitted>
  <study_first_submitted_qc>May 2, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 4, 2016</study_first_posted>
  <results_first_submitted>April 13, 2018</results_first_submitted>
  <results_first_submitted_qc>April 24, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">July 12, 2019</results_first_posted>
  <last_update_submitted>April 24, 2019</last_update_submitted>
  <last_update_submitted_qc>April 24, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">July 12, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Bilastine</keyword>
  <keyword>Montelukast</keyword>
  <keyword>total symptom score</keyword>
  <keyword>AQLQ</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Asthma</mesh_term>
    <mesh_term>Conjunctivitis, Allergic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Montelukast</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <recruitment_details>The recruitment started on 13 April 2016 and termineted on 23 November 2016. 454 patients with SARC and mild to moderate asthma as comorbidity were screened.
420 patients were randomised of which 388 patients completed the study.</recruitment_details>
      <pre_assignment_details>454 patients were enrolled but 34 patients did not met inclusion/exclusion critera.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Bilastine+Montelukast</title>
          <description>Bilastine 20mg
Montelukast 10mg</description>
        </group>
        <group group_id="P2">
          <title>Bilastine Monotherapy</title>
          <description>Bilastine 20mg
Placebo Montelukast 10mg</description>
        </group>
        <group group_id="P3">
          <title>Montelukast Monotherapy</title>
          <description>Montelukast 10mg
Placebo Bilastine 20mg</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="143"/>
                <participants group_id="P2" count="140"/>
                <participants group_id="P3" count="137"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="133"/>
                <participants group_id="P2" count="132"/>
                <participants group_id="P3" count="123"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="8"/>
                <participants group_id="P3" count="14"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Bilastine+Montelukast</title>
          <description>Bilastine 20mg
Montelukast 10mg</description>
        </group>
        <group group_id="B2">
          <title>Bilastine Monotherapy</title>
          <description>Bilastine 20mg
Placebo Montelukast 10mg</description>
        </group>
        <group group_id="B3">
          <title>Montelukast Monotherapy</title>
          <description>Montelukast 10mg
Placebo Bilastine 20mg</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="143"/>
            <count group_id="B2" value="140"/>
            <count group_id="B3" value="137"/>
            <count group_id="B4" value="420"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="143"/>
                    <measurement group_id="B2" value="140"/>
                    <measurement group_id="B3" value="137"/>
                    <measurement group_id="B4" value="420"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="34.9" spread="11.1"/>
                    <measurement group_id="B2" value="35.5" spread="11.0"/>
                    <measurement group_id="B3" value="35.4" spread="10.7"/>
                    <measurement group_id="B4" value="35.2" spread="10.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="69"/>
                    <measurement group_id="B2" value="83"/>
                    <measurement group_id="B3" value="73"/>
                    <measurement group_id="B4" value="225"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="74"/>
                    <measurement group_id="B2" value="57"/>
                    <measurement group_id="B3" value="64"/>
                    <measurement group_id="B4" value="195"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline With Montelukast+Bilastine Compared With Bilastine Monotherapy in SARC Symptoms</title>
        <description>To demonstrate that concomitant administration of montelukast and bilastine is superior to bilastine monotherapy in SARC symptoms, as assessed by Total Symptoms Scores (TSS) after 4 weeks of treatment.
Total Symptoms Scores (TSS) assesses nasal (nasal congestion, rhinorrhea, nasal itching, sneezing) and non nasal symptoms (ocular redness, ocular itching, tearing) of rhinoconjuctivits.
Each of the 7 symptoms is scored from 0 (absent) to 3 (severe) as follows:
0 (absent) Symptom not present
1 (mild) Symptom is clearly present but easily tolerated, a nuisance, minimal awareness
2 (moderate) Symptom is bothersome but tolerable, does not interfere with daily activities or sleep
3 (severe) Symptom is hard to tolerate and interferes with daily activities or sleep.
TSS assessment comprises of scoring (0-3) of all 7 above mentioned symptoms. Final TSS scores is in a range from 0-21.</description>
        <time_frame>4 weeks of treatment (from baseline to 4 weeks of treatment)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Bilastine+Montelukast</title>
            <description>Bilastine 20mg+Montelukast 10mg</description>
          </group>
          <group group_id="O2">
            <title>Bilastine Monotherapy</title>
            <description>Bilastine 20mg
Placebo Montelukast 10mg</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline With Montelukast+Bilastine Compared With Bilastine Monotherapy in SARC Symptoms</title>
          <description>To demonstrate that concomitant administration of montelukast and bilastine is superior to bilastine monotherapy in SARC symptoms, as assessed by Total Symptoms Scores (TSS) after 4 weeks of treatment.
Total Symptoms Scores (TSS) assesses nasal (nasal congestion, rhinorrhea, nasal itching, sneezing) and non nasal symptoms (ocular redness, ocular itching, tearing) of rhinoconjuctivits.
Each of the 7 symptoms is scored from 0 (absent) to 3 (severe) as follows:
0 (absent) Symptom not present
1 (mild) Symptom is clearly present but easily tolerated, a nuisance, minimal awareness
2 (moderate) Symptom is bothersome but tolerable, does not interfere with daily activities or sleep
3 (severe) Symptom is hard to tolerate and interferes with daily activities or sleep.
TSS assessment comprises of scoring (0-3) of all 7 above mentioned symptoms. Final TSS scores is in a range from 0-21.</description>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="143"/>
                <count group_id="O2" value="140"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.2522" lower_limit="-3.8718" upper_limit="-2.6327"/>
                    <measurement group_id="O2" value="-3.4462" lower_limit="-4.0708" upper_limit="-2.8217"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.5721</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.194</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.3429</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.8693</ci_lower_limit>
            <ci_upper_limit>0.4813</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline With Montelukast+Bilastine Compared With Montelukast and Bilastine Monotherapies in Asthma Control</title>
        <description>To evaluate the efficacy of concomitant montelukast and bilastine compared with montelukast and bilastine monotherapies in asthma control, as assessed by Asthma Quality of Life Questionnaire (AQLQ) after 4 weeks.
The AQLQ was developed to measure the functional problems (physical, emotional, social and occupational) that are most troublesome to adults (17-70 years) with asthma.
Each of the 32 questionnaire's items will be scored on a 7-point scale (where 7 means &quot;not impaired at all&quot; and 1 means &quot;severely impaired&quot;). The overall AQLQ score is the mean of all 32 responses (https://www.qoltech.co.uk/aqlq.html).
The change in AQLQ score from baseline to 4 weeks after treatment - AQLQ score at baseline for patients with both available values has been the secondary endpoint.</description>
        <time_frame>After 4 weeks of treatments</time_frame>
        <population>The Intention To Treat population (used for statistical analysis) was 419 patients because 1 patient in Montekukast Monotherapy arm was a drop-out.
The drop-out patient was, instead, included in a Safety Population (420 patients).</population>
        <group_list>
          <group group_id="O1">
            <title>Bilastine+Montelukast</title>
            <description>Bilastine 20mg + Montelukast 10mg</description>
          </group>
          <group group_id="O2">
            <title>Bilastine Monotherapy</title>
            <description>Bilastine 20mg
Placebo Montelukast 10mg</description>
          </group>
          <group group_id="O3">
            <title>Montelukast Monotherapy</title>
            <description>Montelukast 10mg
Placebo Bilastine 20mg</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline With Montelukast+Bilastine Compared With Montelukast and Bilastine Monotherapies in Asthma Control</title>
          <description>To evaluate the efficacy of concomitant montelukast and bilastine compared with montelukast and bilastine monotherapies in asthma control, as assessed by Asthma Quality of Life Questionnaire (AQLQ) after 4 weeks.
The AQLQ was developed to measure the functional problems (physical, emotional, social and occupational) that are most troublesome to adults (17-70 years) with asthma.
Each of the 32 questionnaire's items will be scored on a 7-point scale (where 7 means &quot;not impaired at all&quot; and 1 means &quot;severely impaired&quot;). The overall AQLQ score is the mean of all 32 responses (https://www.qoltech.co.uk/aqlq.html).
The change in AQLQ score from baseline to 4 weeks after treatment - AQLQ score at baseline for patients with both available values has been the secondary endpoint.</description>
          <population>The Intention To Treat population (used for statistical analysis) was 419 patients because 1 patient in Montekukast Monotherapy arm was a drop-out.
The drop-out patient was, instead, included in a Safety Population (420 patients).</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="143"/>
                <count group_id="O2" value="140"/>
                <count group_id="O3" value="136"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.6250" lower_limit="0.4788" upper_limit="0.7712"/>
                    <measurement group_id="O2" value="0.6399" lower_limit="0.4929" upper_limit="0.7870"/>
                    <measurement group_id="O3" value="0.5849" lower_limit="0.4344" upper_limit="0.7353"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0105</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-1.1552</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.4489</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.0379</ci_lower_limit>
            <ci_upper_limit>-0.2725</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline With Montelukast+Bilastine Compared With Montelukast and Bilastine Monotherapies in SARC Symptoms (DNSS)</title>
        <description>To evaluate the efficacy of concomitant montelukast and bilastine compared with montelukast and bilastine monotherapies in daytime symptoms of SARC, as assessed by Daytime Nasal Symptom Score (DNSS) after 4 weeks of treatment.
Daytime Nasal Symptom Score (DNSS) is the average of individual scores of nasal congestion, rhinorrhea, nasal itching, sneezing of rhinoconjuctivits.
Each of the 4 symptoms is scored from 0 (absent) to 3 (severe) as follows:
0 (absent) Symptom not present
1 (mild) Symptom is clearly present but easily tolerated, a nuisance, minimal awareness
2 (moderate) Symptom is bothersome but tolerable, does not interfere with daily activities or sleep
3 (severe) Symptom is hard to tolerate and interferes with daily activities or sleep.
DNSS assessment comprises of scoring (0-3) of all 4 above mentioned symptoms. Final DNSS scores is in a range from 0-12.</description>
        <time_frame>After 4 weeks of treatment (from baseline)</time_frame>
        <population>The Intention To Treat population (used for statistical analysis) was 419 patients because 1 patient in Montekukast Monotherapy arm was a drop-out.
The drop-out patient was, instead, included in a Safety Population (420 patients).</population>
        <group_list>
          <group group_id="O1">
            <title>Bilastine+Montelukast</title>
            <description>Bilastine 20mg
Montelukast 10mg</description>
          </group>
          <group group_id="O2">
            <title>Bilastine Monotherapy</title>
            <description>Bilastine 20mg
Placebo Montelukast 10mg</description>
          </group>
          <group group_id="O3">
            <title>Montelukast Monotherapy</title>
            <description>Montelukast 10mg
Placebo Bilastine 20mg</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline With Montelukast+Bilastine Compared With Montelukast and Bilastine Monotherapies in SARC Symptoms (DNSS)</title>
          <description>To evaluate the efficacy of concomitant montelukast and bilastine compared with montelukast and bilastine monotherapies in daytime symptoms of SARC, as assessed by Daytime Nasal Symptom Score (DNSS) after 4 weeks of treatment.
Daytime Nasal Symptom Score (DNSS) is the average of individual scores of nasal congestion, rhinorrhea, nasal itching, sneezing of rhinoconjuctivits.
Each of the 4 symptoms is scored from 0 (absent) to 3 (severe) as follows:
0 (absent) Symptom not present
1 (mild) Symptom is clearly present but easily tolerated, a nuisance, minimal awareness
2 (moderate) Symptom is bothersome but tolerable, does not interfere with daily activities or sleep
3 (severe) Symptom is hard to tolerate and interferes with daily activities or sleep.
DNSS assessment comprises of scoring (0-3) of all 4 above mentioned symptoms. Final DNSS scores is in a range from 0-12.</description>
          <population>The Intention To Treat population (used for statistical analysis) was 419 patients because 1 patient in Montekukast Monotherapy arm was a drop-out.
The drop-out patient was, instead, included in a Safety Population (420 patients).</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="143"/>
                <count group_id="O2" value="140"/>
                <count group_id="O3" value="136"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.9713" lower_limit="-2.3442" upper_limit="-1.5984"/>
                    <measurement group_id="O2" value="-2.1106" lower_limit="-2.4863" upper_limit="-1.7349"/>
                    <measurement group_id="O3" value="-1.8678" lower_limit="-2.2468" upper_limit="-1.4888"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.4885</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.1393</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.2009</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.5342</ci_lower_limit>
            <ci_upper_limit>0.2557</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline With Montelukast + Bilastine Compared With Montelukast and Bilastine Monotherapies in SARC Symptoms (DNNSS)</title>
        <description>To evaluate the efficacy of concomitant montelukast and bilastine compared with montelukast and bilastine monotherapies in daytime symptoms of SARC, as assessed by Daytime Non Nasal Symptom Score (DNNSS) after 4 weeks of treatment.
Daytime Non Nasal Symptom Score (DNSS) is the average of individual scores of ocular redness, ocular itching and tearing of rhinoconjuctivits.
Each of the 3 symptoms is scored from 0 (absent) to 3 (severe) as follows:
0 (absent) Symptom not present
1 (mild) Symptom is clearly present but easily tolerated, a nuisance, minimal awareness
2 (moderate) Symptom is bothersome but tolerable, does not interfere with daily activities or sleep
3 (severe) Symptom is hard to tolerate and interferes with daily activities or sleep.
DNNSS assessment comprises of scoring (0-3) of all 3 above mentioned symptoms. Final DNNSS scores is in a range from 0-9.</description>
        <time_frame>After 4 weeks of treatment (from baseline)</time_frame>
        <population>The Intention To Treat population (used for statistical analysis) was 419 patients because 1 patient in Montekukast Monotherapy arm was a drop-out.
The drop-out patient was, instead, included in a Safety Population (420 patients).</population>
        <group_list>
          <group group_id="O1">
            <title>Bilastine+Montelukast</title>
            <description>Bilastine 20mg + Montelukast 10mg</description>
          </group>
          <group group_id="O2">
            <title>Bilastine Monotherapy</title>
            <description>Bilastine 20mg
Placebo Montelukast 10mg</description>
          </group>
          <group group_id="O3">
            <title>Montelukast Monotherapy</title>
            <description>Montelukast 10mg
Placebo Bilastine 20mg</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline With Montelukast + Bilastine Compared With Montelukast and Bilastine Monotherapies in SARC Symptoms (DNNSS)</title>
          <description>To evaluate the efficacy of concomitant montelukast and bilastine compared with montelukast and bilastine monotherapies in daytime symptoms of SARC, as assessed by Daytime Non Nasal Symptom Score (DNNSS) after 4 weeks of treatment.
Daytime Non Nasal Symptom Score (DNSS) is the average of individual scores of ocular redness, ocular itching and tearing of rhinoconjuctivits.
Each of the 3 symptoms is scored from 0 (absent) to 3 (severe) as follows:
0 (absent) Symptom not present
1 (mild) Symptom is clearly present but easily tolerated, a nuisance, minimal awareness
2 (moderate) Symptom is bothersome but tolerable, does not interfere with daily activities or sleep
3 (severe) Symptom is hard to tolerate and interferes with daily activities or sleep.
DNNSS assessment comprises of scoring (0-3) of all 3 above mentioned symptoms. Final DNNSS scores is in a range from 0-9.</description>
          <population>The Intention To Treat population (used for statistical analysis) was 419 patients because 1 patient in Montekukast Monotherapy arm was a drop-out.
The drop-out patient was, instead, included in a Safety Population (420 patients).</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="143"/>
                <count group_id="O2" value="140"/>
                <count group_id="O3" value="136"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.2824" lower_limit="-1.5667" upper_limit="-0.9980"/>
                    <measurement group_id="O2" value="-1.3185" lower_limit="-1.6051" upper_limit="-1.0320"/>
                    <measurement group_id="O3" value="-1.1574" lower_limit="-1.4462" upper_limit="-0.8687"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.81032</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.03615</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.1504</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.3319</ci_lower_limit>
            <ci_upper_limit>0.2596</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Usage of Relief Medication for SARC</title>
        <description>Number of days without any relief medication for SARC</description>
        <time_frame>From baseline to 4 weeks of treatment</time_frame>
        <population>The Intention To Treat population (used for statistical analysis) was 419 patients because 1 patient in Montekukast Monotherapy arm was a drop-out.
The drop-out patient was, instead, included in a Safety Population (420 patients).</population>
        <group_list>
          <group group_id="O1">
            <title>Bilastine+Montelukast</title>
            <description>Bilastine 20mg + Montelukast 10mg</description>
          </group>
          <group group_id="O2">
            <title>Bilastine Monotherapy</title>
            <description>Bilastine 20mg
Placebo Montelukast 10mg</description>
          </group>
          <group group_id="O3">
            <title>Montelukast Monotherapy</title>
            <description>Montelukast 10mg
Placebo Bilastine 20mg</description>
          </group>
        </group_list>
        <measure>
          <title>Usage of Relief Medication for SARC</title>
          <description>Number of days without any relief medication for SARC</description>
          <population>The Intention To Treat population (used for statistical analysis) was 419 patients because 1 patient in Montekukast Monotherapy arm was a drop-out.
The drop-out patient was, instead, included in a Safety Population (420 patients).</population>
          <units>Days</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="143"/>
                <count group_id="O2" value="140"/>
                <count group_id="O3" value="136"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.0057" spread="0.8260"/>
                    <measurement group_id="O2" value="15.8416" spread="0.8326"/>
                    <measurement group_id="O3" value="15.4179" spread="0.8411"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.3704</p_value>
            <method>ANOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.8359</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.9322</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.9969</ci_lower_limit>
            <ci_upper_limit>2.6688</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Usage of Relief Medication for Asthma</title>
        <description>Number of days without any relief medication for Asthma.</description>
        <time_frame>From baseline to 4 weeks of treatment</time_frame>
        <population>The Intention To Treat population (used for statistical analysis) was 419 patients because 1 patient in Montekukast Monotherapy arm was a drop-out.
The drop-out patient was, instead, included in a Safety Population (420 patients).</population>
        <group_list>
          <group group_id="O1">
            <title>Bilastine+Montelukast</title>
            <description>Bilastine 20mg + Montelukast 10mg</description>
          </group>
          <group group_id="O2">
            <title>Bilastine Monotherapy</title>
            <description>Bilastine 20mg
Placebo Montelukast 10mg</description>
          </group>
          <group group_id="O3">
            <title>Montelukast Monotherapy</title>
            <description>Montelukast 10mg
Placebo Bilastine 20mg</description>
          </group>
        </group_list>
        <measure>
          <title>Usage of Relief Medication for Asthma</title>
          <description>Number of days without any relief medication for Asthma.</description>
          <population>The Intention To Treat population (used for statistical analysis) was 419 patients because 1 patient in Montekukast Monotherapy arm was a drop-out.
The drop-out patient was, instead, included in a Safety Population (420 patients).</population>
          <units>Days</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="143"/>
                <count group_id="O2" value="140"/>
                <count group_id="O3" value="136"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="53.2548" spread="2.0193"/>
                    <measurement group_id="O2" value="52.4177" spread="2.0212"/>
                    <measurement group_id="O3" value="50.7146" spread="2.0768"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.7452</p_value>
            <method>ANOVA</method>
            <param_type>Median Difference (Final Values)</param_type>
            <param_value>-0.837</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>2.5735</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-5.8968</ci_lower_limit>
            <ci_upper_limit>4.2228</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Bilastine+Montelukast</title>
          <description>Bilastine 20 mg, 10 blister containing 10 tablets + Montelukast 10 mg, 10 blister containing 10 film coated tablets each for treatment
Bilastine 20mg
Montelukast 10mg</description>
        </group>
        <group group_id="E2">
          <title>Bilastine+Placebo Montelukast</title>
          <description>Bilastine 20 mg, 10 blister containing 10 tablets + Placebo Montelukast, 10 blister containing 10 film coated tablets each.
Bilastine 20mg
Placebo Montelukast 10mg</description>
        </group>
        <group group_id="E3">
          <title>Montelukast+Placebo Bilastine</title>
          <description>Placebo Bilastine, 10 blister containing 10 tablets + Montelukast 10 mg, 10 blister containing 10 film coated tablets each.
Montelukast 10mg
Placebo Bilastine 20mg</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="137"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal Pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="137"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="143"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="140"/>
                <counts group_id="E3" subjects_affected="14" subjects_at_risk="137"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Vertigo</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="140"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="137"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Gastrooesophageal Reflux Disease</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="137"/>
              </event>
              <event>
                <sub_title>Gingival Bleeding</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="137"/>
              </event>
              <event>
                <sub_title>Hypoaesthesia oral</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="137"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="140"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="137"/>
              </event>
              <event>
                <sub_title>Oedema Peripheral</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="137"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Alanine Aminotransferase Increased</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="143"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="137"/>
              </event>
              <event>
                <sub_title>Aspartate Aminotransferase Increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="143"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="137"/>
              </event>
              <event>
                <sub_title>Gamma-glutamytrasferase Increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="143"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="137"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Increased appetite</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="143"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="140"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="137"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="137"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="143"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="137"/>
              </event>
              <event>
                <sub_title>Hypoaesthesia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="137"/>
              </event>
              <event>
                <sub_title>Sedation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="143"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="137"/>
              </event>
              <event>
                <sub_title>Somnolence</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="143"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="140"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="137"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="137"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="143"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="137"/>
              </event>
              <event>
                <sub_title>Irritability</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="137"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Medical Director</name_or_title>
      <organization>Menarini International Operations Luxembourg SA</organization>
      <phone>+352 2649761</phone>
      <email>aconte@menarini.lu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

